Ginkgo Bioworks is using the $1.6 billion it raised in September to advance its lead in synthetic
biology, developing a catalog of molecular building blocks that customers can use to create new drugs, foods, and materials.
I spent half a billion
dollars on things already and were going to keep spending, Ginkgo CEO Jason Kelly said at the J.P. Morgan Healthcare Conference last week. Building the technology platform may be expensive, but thanks to the SPAC merger, that money
is in the bank, he said.
Indeed, its too soon to declare that the newly public companies have failed, said David Ethridge, the US IPO
services leader at PwC who previously headed the New York Stock Exchanges IPO efforts.
Its a longer-term thing thats got to play
out, Ethridge said. Not just one quarter, but maybe the next year. Lets see how they do over a four- or five-quarter period.
Which brings us to the future of the Boston tech scene.
Gelesis, the weight-loss device maker that went public last week, raised $105 million from its deal, less than
one-third the $376 million it originally hoped for, as many SPAC investors exercised their right to bail out before the merger was completed. The initial excitement about SPACs as a vehicle has
shifted, Gelesis chief executive Yishai Zohar conceded.
Among the remaining SPAC deals pending, crypto company Circle Internet Finance, battery
maker SES, and biotech GreenLight Biosciences had each said that they planned to close by the end of 2021 but didnt make it.
More recent deals by
wireless Internet service Starry, weather and climate tracker Tomorrow.io, and warehouse robotics maker Symbotic are also still pending.
Starry chief
executive Chet Kanojia remains upbeat that his SPAC deal will be completed successfully. We feel pretty good, he said. Weve been talking to a lot of investors and ... they understand that were in the earliest stage of
growth.
Given the poor stock performance so far, however, the SPAC market is starting to adjust and offer better terms to investors and more limits
on the profits of sponsors, according to Jay Ritter, a professor at the University of Florida who has been tracking the IPO market for decades.
The
market has been evolving, Ritter said. SPACs are a viable option for [some] operating companies thinking of going public, though most companies will still use a traditional IPO, he said.
Jeff Bussgang, general partner at Flybridge Capital Partners, would agree. SPACs will continue to be a pretty useful vehicle, he said,
particularly for local companies that are based on cutting-edge science and technology and are looking to go public.